Prognostic significance of peritumoral lymphatic vessel density and vascular endothelial growth factor receptor 3 in invasive squamous cell cervical cancer

Translational Oncology

Volumn 3, Issue 3, 2010, Pages 170-175

  Botting, Shaleen K ^a   Fouad, Hala ^a   Elwell, Kyler ^a   Rampy, Bill A ^a   Salama, Salama A ^a   Freeman, Daniel H ^b   Diaz Arrastia, Concepcion R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY D2-40; PROTEIN TYROSINE KINASE; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADULT; ARTICLE; CANCER INVASION; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PROGNOSIS; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

EID: 77954669032     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09292     Document Type: Article

References (28)

1. Van Trappen PO and Pepper MS (2005). Lymphangiogenesis in human gynaecological cancers. Angiogenesis 8, 137-145.
2. Saliarinen P, Tammela T, Karkkainen MJ, and Alitalo K (2004). Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25, 387-395.
3. Van Trappen PO and Pepper MS (2002). Lymphatic dissemination of tumour cells and the formation of micrometastases. Lancet Oncol 3, 44-52.
4. Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, and Vermeulen PB (2006). First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br] Cancer 95, 1611-1625.
5. Pepper MS, Tille JC, Nisato R, and Skobe M (2003). Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314, 167-177.
6. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, and Ristamaki R (2003). Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63, 1920-1926.
7. Fogt F, Zimmerman RL, Ross HM, Daly T, and Gausas RE (2004). Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep 11, 47-50.
8. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, et al. (2001). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20, 1223-1231.
9. Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, and Acs G (2005). Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 18, 97-104.
10. Urabe A, Matsumoto T, Kimura M, Sonoue H, and Kinoshita K (2006). Grading system of lymphatic invasion according to D2-40 immunostaining is useful for the prediction of nodal metastasis in squamous cell carcinoma of the uterine cervix. Histopathology 49, 493-497.
11. Zaino RJ (2002). Lymph-vascular space invasion in endometrial adenocarcinoma: confusion, confessions, and conclusions. Gynecol Oncol 87, 240-242.
12. Lee AH, Pinder SE, Macmillan RD, Mitchell M, Ellis IO, Elston CW, and Blarney RW (2006). Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 42, 357-362.
13. Kiruparan P and Forrest L (2007). Prediction in breast cancer of the extent of axillary node involvement from the size and lymphovascular invasion status of the primary tumour: medico-legal considerations. Eur J Surg Oncol 33, 435-437.
14. Hove MG, DinhTV, HanniganEV, LucciJA III, Chopra V, SmithER, and ToT (1999). Oncogene expression and microvessel count in recurrent and nonrecurrent stage lb squamous cell carcinoma of the cervix./Reprod Med 44, 493-496.
15. Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, and Van Marck EA (2006). Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 94, 1643-1649.
16. Roman LD, Felix JC, Muderspach LI, Varkey T, Burnett AF, Qian D, and Morrow CP (1998). Influence of quantity of lymph-vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. Gynecol Oncol 68, 220-225.
17. Kahn HJ and Marks A (2002). A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 82, 1255-1257.
18. Xuan M, Fang YR, Wato M, Hata S, and Tanaka A (2005). Immunohistochemical co-localization of lymphatics and blood vessels in oral squamous cell carcinomas.j Oral Pathol Med 34, 334-339.
19. Pecorelli S, Benedet JL, Creasman WT, and Shepherd JH (1999). FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Lnt] Gynaecol Obstet 65, 243-249.
20. Richard SD, Krivak TC, Castleberry A, Beriwal S, Kelley JL III, Edwards RP, and Sukumvanich P (2008). Survival for stage IB cervical cancer with positive lymph node involvement: a comparison of completed vs. abandoned radical hysterectomy. Gynecol Oncol 109, 43-48.
21. Ayhan A, Al RA, Baykal C, Demirtas E, Ayhan A, and Yuce K (2004). Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy. Lnt] Gynecol Cancer 14, 286-292.
22. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, and Zaino RJ (1999). A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73, 177-183.
23. Peters WA III, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, and Alberts DS (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18, 1606-1613.
24. Schoppmann SF, Birner P, Studer P, and Breiteneder-Geleff S (2001). Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 21, 2351-2355.
25. Padera TR Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886.
26. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, and Jain RK (2000). Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60, 4324-4327.
27. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, and Ayala G (2004). Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 58, 193-199.
28. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, and Tilley WD (2002). A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62, 854-859.